Logo
Dermaqual SUPRÉALL

Dermaqual SUPRÉALL

Dermaqual

Cosmetic / Mesotherapy solution
  • Manufactured by Dermaqual SARL, a French aesthetic and cosmetic laboratory supplying professional mesotherapy and lipolysis solutions.
  • Marketed as a professional mesotherapy/lipolytic cocktail rather than as a licensed medicinal product; regulatory classification and approval route vary by country.
  • Intended to be used only in compliance with local regulations governing lipolysis injections, mesotherapy, and the use of phosphatidylcholine/deoxycholate formulations by qualified healthcare professionals.
  • Clinics using SUPRÉALL must adhere to applicable standards on informed consent, patient selection, record Keeping, aseptic technique and post Procedure monitoring.
Phosphatidylcholine + deoxycholate lipolytic meso-cocktail

Description

SUPRÉALL is a clear, colourless, sterile lipolytic (cytolytic) mesotherapy solution from Dermaqual, formulated to combat undesirable localized fat deposits and the appearance of cellulite. This expert slimming cocktail combines deoxycholic acid (a cytolytic bile acid) with phosphatidylcholine in a PC–DC complex, supported by vitamin E (tocopherol), to selectively destroy adipocytes and reduce moderate fat deposits that do not respond well to diet and exercise. It is positioned as a non-invasive alternative to liposuction and other fat-reducing procedures, particularly for submental contouring (double chin) and body-contouring indications in appropriately selected adult patients, and is intended strictly for professional use within mesotherapy and lipolysis treatment protocols.

Bnefits

  • Targets localized, soft and moderate fat deposits that are resistant to diet and exercise, including submental fat and body contour irregularities.
  • Provides non-surgical body contouring and is marketed as an alternative to liposuction for selected localized fat indications.
  • Combines deoxycholic acid and phosphatidylcholine (PC–DC complex) for synergistic adipocytolytic effect on fat cells.
  • Helps minimize the appearance of cellulite and smooth skin contour irregularities, including post-liposuction deformities and depressed scars bordered by protruding fat.
  • Provides submental contouring of the jawline and double chin without anesthesia, scars or significant downtime when performed by trained professionals.
  • Acts directly on fat-lipolytic pathways and promotes programmed cell death (apoptosis) of adipocytes, with effects continuing over 8–12 weeks after treatment initiation.
  • Targets only adipose tissue according to manufacturer description, with nerves and muscles reported as unaffected when used correctly.
  • Suitable for both men and women with appropriate localized fat indications.
  • Integrates into broader body and facial contouring mesotherapy protocols, complementing diet, exercise and other aesthetic treatments.

Indications

  • Submental contouring (double chin) and reshaping of the submandibular jawline.
  • Moderate, soft localized fat deposits ("spongy" fat) on body areas that are difficult to reduce with diet and physical activity alone.
  • Silhouette reshaping and body contour refinement, especially in small to medium fat pockets.
  • Reduction in the appearance of cellulite and surface irregularities associated with adipose tissue.
  • Correction of residual localized fat and contour irregularities after liposuction (e.g. small lipomas, post-lipo deformities, traumatic fat necrosis).
  • Depressed post-cesarean scars bordered by protruding fat and other small localized bulges where protocol indicates.
  • General indications listed as: submental neck area and submandibular jawline, lower and upper abdomen, arms, shoulders, thighs, oblique/flank areas and other localized soft-fat areas deemed appropriate by the practitioner.

Composition

  • Aqua / Water
  • Sodium Deoxycholate (deoxycholic acid salt)
  • Phosphatidylcholine (PC)
  • Tocopherol (Vitamin E)
  • Benzyl Alcohol
  • Sodium Chloride
  • Sodium Hydroxide

Formulation

  • Clear, colourless, sterile lipolytic (cytolytic) solution for professional mesotherapy/lipolysis use.
  • PC–DC complex combining phosphatidylcholine with sodium deoxycholate as the main active lipolytic ingredients.
  • Contains vitamin E (tocopherol) as an antioxidant component, plus excipients such as benzyl alcohol, sodium chloride and sodium hydroxide to adjust preservation, tonicity and pH.
  • Designed to selectively damage adipocyte membranes and promote adipocyte apoptosis via a cascade of enzymatic reactions.
  • Non-viscous solution suitable for controlled mesotherapy delivery by trained practitioners.

Packaging

  • Manufacturer standard: box with 5 sterile vials × 10 ml (0.34 fl. oz) each.
  • Some distributors offer individual sterile vials (e.g. 1 × 5 ml or 1 × 10 ml) for single-patient clinical use.
  • Vials are labelled with product name (SUPRÉALL), batch/lot number, expiry date and basic composition.
  • Outer carton designed for professional clinic storage, with product category indicated as mesotherapy / lipolysis solution.

Usage

  • For professional use only; must be used exclusively by qualified medical or aesthetic practitioners with specific training in lipolysis and mesotherapy procedures.
  • Conduct a full medical history and localized fat assessment to ensure appropriate indication, rule out contraindications and set realistic expectations with informed consent.
  • Mark treatment zones carefully (e.g. submental region, abdomen, arms, thighs) and document baseline photographs where appropriate.
  • Cleanse and disinfect the treatment area thoroughly using aseptic technique; use sterile equipment and gloves.
  • Administration is typically via mesotherapy lipolysis techniques (e.g. micro-injections to the superficial subcutaneous fat layer, or in some protocols, micro-needling/topical meso-delivery) following the official Dermaqual protocol and local regulatory guidance.
  • When injection techniques are used, deposit small, evenly spaced aliquots into the subcutaneous fat layer while avoiding intravascular injection, nerves and deeper structures; maintain appropriate depth and spacing based on anatomical landmarks.
  • Do not inject intradermally, intramuscularly or intravascularly; avoid highly vascular or high-risk anatomical areas unless specifically trained and guided by evidence-based protocols.
  • A typical course consists of multiple sessions (for example, every 2–4 weeks) over a 2–3 month period, with cumulative lipolytic effects continuing up to 8–12 weeks from the first treatment; exact number of sessions, injection grid and dose per area should follow official protocol and individual patient factors.
  • Use each vial for a single patient only; any unused solution after a session must be discarded and not stored or reused.
  • After treatment, lightly massage only if protocol dictates; advise patients about expected post-procedure reactions (swelling, tenderness, bruising) and aftercare (e.g. avoiding NSAIDs if not medically necessary, avoiding heat exposure, intense exercise, saunas and hot baths for at least 24–48 hours).
  • Instruct patients to seek immediate medical attention if they experience severe pain, signs of infection, tissue necrosis, difficulty swallowing, breathing issues or any unusual or severe adverse effects.
  • Clinics must follow national/local regulations for lipolysis injections, including any restrictions on who can administer PC–DC solutions.

Contraindications

  • Known hypersensitivity or allergy to any of the components (e.g. sodium deoxycholate, phosphatidylcholine, benzyl alcohol, tocopherol or excipients).
  • Pregnancy and breastfeeding (lipolysis mesotherapy with PC–DC is generally avoided due to lack of safety data in these populations).
  • Patients with severe systemic illness, uncontrolled diabetes, significant hepatic or renal impairment, or uncontrolled autoimmune disease, unless specifically cleared by a physician.
  • Active skin infections, dermatitis, open wounds, or inflammatory conditions at or near the intended treatment area.
  • History of severe anaphylaxis, significant hypersensitivity reactions or severe adverse events with previous lipolysis injections.
  • Bleeding disorders or current use of significant anticoagulant/antiplatelet therapy that cannot be safely managed, increasing risk of bleeding or hematoma.
  • Unrealistic expectations or generalized obesity where local lipolysis treatments are not appropriate substitutes for weight management.
  • Previous pathological scarring or keloid tendency in treatment zones, if judged clinically significant by the practitioner.
  • Any formal contraindications contained in the latest official Dermaqual documentation, local medical device/cosmetic regulations, or national guidance on phosphatidylcholine/deoxycholate lipolysis injections.

Adverse Effects

  • Common, usually transient local reactions at the treatment site: erythema (redness), edema (swelling), warmth, tenderness, itching or burning sensation.
  • Bruising, hematoma and localized pain, particularly in areas with dense vascularity or where multiple injections are required.
  • Firmness, induration or palpable nodules in the treated fat area, usually resolving over days to weeks as lipolysis and tissue remodeling occur.
  • Temporary sensitivity or altered sensation in the treated region.
  • Post-inflammatory hyperpigmentation or localized discoloration in some skin types, particularly if aftercare and sun protection are inadequate.
  • Local infection or abscess formation if aseptic technique is not strictly followed.
  • Rare but potentially serious complications associated with lipolysis injections, such as tissue necrosis, ulceration, nerve injury, vascular compromise or severe inflammatory reactions, especially if product is injected too superficially, too deeply, intravascularly or in contraindicated areas.
  • Rare systemic reactions or hypersensitivity/allergic responses to active ingredients or excipients.
  • Adverse event risk is significantly reduced when treatment is carried out by suitably trained professionals following evidence-based protocols and local regulations.

Storage Conditions

  • Store in a cool, dry place away from direct sunlight and excessive heat, in accordance with the storage instructions printed on the packaging.
  • Keep vials in their original outer carton until use to protect from light and environmental factors.
  • Do not freeze; extreme temperatures may destabilize the solution or components.
  • Do not use after the expiry date indicated on vial and carton.
  • Do not use if the vial, closure or packaging is cracked, leaking or shows evidence of compromised sterility.
  • Once opened, use immediately during a single treatment session and discard any remaining product.

Duration

According to manufacturer and distributor information, SUPR\u00c9ALL therapy is designed to permanently reduce or eliminate localized fat deposits within approximately 12 weeks of therapy. Biochemical adipocyte destruction begins after the first session and continues for 8\u201312 weeks, with treatment courses typically spanning several sessions over 2\u20133 months followed by clinical review and possible touch-up sessions if required.

Onset

Biochemical adipocytolysis begins immediately after the first treatment, with progressive visible improvement (reduction of fat bulge and smoothing of contour) developing over the following weeks. Noticeable contour changes are commonly observed within 4\u20138 weeks, with full effect often evident by about 8\u201312 weeks after starting a complete treatment course, depending on treatment area, dose, and individual response.

Browse more Cosmetic / Mesotherapy solution

Top Treatments

Top Cities in the UK